Cheryl Willman's research group focuses primarily on the characterization and targeted therapies of human leukemia. The bulk of the characterization work centers on the integration of gene expression patterns with underlying genetic events to identify groups of patients with targetable characteristics. By taking advantage of the specific features of these expression groups it is possible to develop focused therapies to treat these patients with maximum efficacy and minimal side effects. Over the past several years, this discovery effort has branched over into targeted therapeutics as well. In conjunction with UNM and Sandia colleagues the group is now exploring the application of nanotechnology as targeted delivery vectors for therapeutic agents. The discoveries stemming from these efforts will likely be applicable to many other cancers.